JP2005535675A - 変異型ｒｅｔキナーゼ関連疾患を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド - Google Patents

変異型ｒｅｔキナーゼ関連疾患を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド Download PDF

Info

Publication number
JP2005535675A
JP2005535675A JP2004522385A JP2004522385A JP2005535675A JP 2005535675 A JP2005535675 A JP 2005535675A JP 2004522385 A JP2004522385 A JP 2004522385A JP 2004522385 A JP2004522385 A JP 2004522385A JP 2005535675 A JP2005535675 A JP 2005535675A
Authority
JP
Japan
Prior art keywords
methyl
ylmethyl
benzamide
phenyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004522385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535675A5 (enExample
Inventor
ジェイムズ・アレキサンダー・フェイギン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of JP2005535675A publication Critical patent/JP2005535675A/ja
Publication of JP2005535675A5 publication Critical patent/JP2005535675A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004522385A 2002-07-24 2003-05-23 変異型ｒｅｔキナーゼ関連疾患を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド Pending JP2005535675A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39840902P 2002-07-24 2002-07-24
PCT/IB2003/001984 WO2004009087A1 (en) 2002-07-24 2003-05-23 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases

Publications (2)

Publication Number Publication Date
JP2005535675A true JP2005535675A (ja) 2005-11-24
JP2005535675A5 JP2005535675A5 (enExample) 2006-07-06

Family

ID=30771216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004522385A Pending JP2005535675A (ja) 2002-07-24 2003-05-23 変異型ｒｅｔキナーゼ関連疾患を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド

Country Status (8)

Country Link
US (2) US20060116381A1 (enExample)
EP (1) EP1526854A1 (enExample)
JP (1) JP2005535675A (enExample)
CN (1) CN1668306A (enExample)
AU (1) AU2003232960A1 (enExample)
BR (1) BR0312873A (enExample)
CA (1) CA2493000A1 (enExample)
WO (1) WO2004009087A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535967A (ja) * 2015-11-02 2018-12-06 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
CN112574201B (zh) * 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
KR20230017234A (ko) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 프랄세티닙의 고체 형태

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504834A (ja) * 1993-10-01 1996-05-28 チバ−ガイギー アクチェンゲゼルシャフト 更に付け加えられたピリミジン誘導体およびそれらの製法
JP2001510192A (ja) * 1997-07-18 2001-07-31 ノバルティス アクチエンゲゼルシャフト Ｎ−フェニル−２−ピリミジンアミン誘導体の結晶変形、その製造法およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504834A (ja) * 1993-10-01 1996-05-28 チバ−ガイギー アクチェンゲゼルシャフト 更に付け加えられたピリミジン誘導体およびそれらの製法
JP2001510192A (ja) * 1997-07-18 2001-07-31 ノバルティス アクチエンゲゼルシャフト Ｎ−フェニル−２−ピリミジンアミン誘導体の結晶変形、その製造法およびその使用

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6010001817, Ｅｎｄｏｃｒｉｎｏｌｏｇｙ, 200206, Ｖｏｌ．１４３， Ｎｏ．６, ｐ．２０２５−２０２８ *
JPN6010001820, Ｔｈｅ Ｎｅｗ Ｅｎｇｌａｎｄ Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎｅ, 200104, Ｖｏｌ．３４４， Ｎｏ．１４, ｐ．１０５２−１０５６ *
JPN6010001823, Ｏｎｃｏｇｅｎｅ, 2000, Ｖｏｌ．１９, ｐ．３５２１−３５２８ *
JPN6010001826, Ｂｌｏｏｄ, 2000, Ｖｏｌ．９６， Ｎｏ．３, ｐ．９２５−９３２ *
JPN6010001828, Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 1996, Ｖｏｌ．５６, ｐ．１００−１０４ *
JPN6010001831, Ｃｌｉｎｉｃａｌ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 200202, Ｖｏｌ．８, ｐ．３６１−３６７ *
JPN6010001834, Ｂｉｏｃｈｅｍ． Ｂｉｏｐｈｙｓ． Ｒｅｓ． Ｃｏｍｍｕｎ．, 1995, Ｖｏｌ．２０７， Ｎｏ．３, ｐ．１０２２−１０２８ *
JPN6010001836, Ｏｎｃｏｇｅｎｅ, 2000, Ｖｏｌ．１９, ｐ．５５９０−５５９７ *
JPN6010001838, Ｉｎｔ． Ｊ． Ｃａｎｃｅｒ, 2000, Ｖｏｌ．８５, ｐ．３８４−３９０ *
JPN6010001840, Ｊ． Ｐｈａｒｍａｃｏｌ． Ｅｘｐ． Ｔｈｅｒ．, 2000, Ｖｏｌ．２９５， Ｎｏ．１, ｐ．１３９−１４５ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535967A (ja) * 2015-11-02 2018-12-06 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤
JP2021036004A (ja) * 2015-11-02 2021-03-04 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤
JP7026196B2 (ja) 2015-11-02 2022-02-25 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤

Also Published As

Publication number Publication date
AU2003232960A1 (en) 2004-02-09
CN1668306A (zh) 2005-09-14
WO2004009087A1 (en) 2004-01-29
EP1526854A1 (en) 2005-05-04
US20060116381A1 (en) 2006-06-01
US20070265274A1 (en) 2007-11-15
BR0312873A (pt) 2005-06-28
CA2493000A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
US20070265274A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
Roskoski Jr ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
JP2005531488A (ja) 甲状腺癌を処置するためのｅｇｆ受容体阻害剤
US7211600B2 (en) Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
USRE37650E1 (en) Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
RS66727B1 (sr) Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
JP6949726B2 (ja) Ｅｇｆｒ変異癌を治療する方法
TW201400485A (zh) 吡咯并吡咯啶酮化合物
RU2660354C2 (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
JP2007502807A (ja) Ｅｒｂｂ２抗がん剤の投与スケジュール
BR112019014127A2 (pt) Composição farmacêutica para tratamento de tumores
HK1243352A1 (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
PT2182948E (pt) Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
RU2695230C2 (ru) Сочетанная терапия
Burkholder et al. Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model
AU2013243737B2 (en) Tyrosine kinase inhibitor combinations and their use
AU2014396394A1 (en) 1H-1,8- naphthyridin-2ones as anti proliferative compounds
De Bree et al. Imatinib mesilate
US9956221B2 (en) Use of a receptor-type kinase modulator for treating polycystic kidney disease
US20030191131A1 (en) Use of organic compounds
JP2005508846A (ja) アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用
Ram Blocking HER-2-Mediated Transformation with a Dominant Negative Form of HER-3
NZ547214A (en) Use of N-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727